Updated:
CureDuchenne Ventures
CureDuchenne is a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy. It uses an innovative venture philanthropy model that...
CureDuchenne Ventures
CureDuchenne is a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy. It uses an innovative venture philanthropy model that funds groundbreaking research, early diagnosis and treatment access, along with education and support programs for families affected by the disease.
General information
Firm type
Venture Capital
Year founded
2014
Location
Region
North America
Country
United States
City
Newport Beach
Corporate office
Newport Beach, CA, United States
Principals
Debra Miller
Founder & CEO
Michael G. Kelly
Chief Scientific Officer
Paul Miller
co-founder
Sector focus
Frequently asked questions
Is CureDuchenne Ventures a traditional venture capital fund?
No. It is the venture-philanthropy arm of a registered nonprofit, not a for-profit fund with limited partners. Because its capital comes from donations rather than institutional investors demanding market-rate returns, the firm can underwrite higher scientific risk and accept longer time horizons. Any financial returns from exits are recycled back into CureDuchenne's grantmaking and research programs rather than distributed to partners.
Who runs investment decisions at CureDuchenne Ventures?
The firm does not publicly list a dedicated investment team or managing partner. Investment decisions appear to be made by the nonprofit's founder Debra Miller alongside a scientific advisory board of Duchenne researchers and clinicians. This tight, science-first governance model is common in disease-focused venture philanthropy, where the investment committee looks more like a peer-review panel than a traditional GP group.
Does CureDuchenne Ventures co-invest with outside venture capital firms?
Yes. The firm regularly co-invests alongside traditional biotech venture funds, often as the first institutional capital into a Duchenne-focused startup. Later-stage syndicates have included top-tier life-science investors such as RA Capital and Atlas Venture, with CureDuchenne Ventures bringing patient-community access and disease-specific scientific validation that a generalist biotech fund cannot offer.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: